Amneal Pharmaceuticals, Inc. Q2 FY2026 earnings call

Strategic Transformation and Portfolio Diversification

• Amneal is in the most transformative period in its history, building toward becoming the leading U.S. affordable medicines company with a diversified portfolio including complex generics, specialty brands, biosimilars, and GLP-1 peptides.
• The company has achieved seven consecutive years of top and bottom line growth, with Q2 2026 adjusted EBITDA of $206 million (up 12% YoY) and adjusted EPS of $0.30 (up 20% YoY).

Biosimilar Growth Platform (via pending Kashiv Acquisition)

• The pending acquisition of Kashiv will create a fully integrated end-to-end global biosimilar platform, spanning cell line development through commercial manufacturing and U.S. commercialization.
• The U.S. biosimilar market is entering a major growth cycle, with 118 biologics expected to lose exclusivity over the next decade; 75% of Amneal's biosimilar portfolio will target lower-competition opportunities, with 25% targeting large-volume markets.
• Kashiv's drug substance manufacturing capacity will expand from ~26,000 liters (end-2026) to ~75,000 liters (2028), and the combined pipeline includes over 20 biosimilar programs, supporting new launches through the 2030s.

Operational and Supply Chain Strength

• Amneal's global diversified manufacturing network, with investments in digitization, automation and AI, is a core competitive advantage focused on supply chain resiliency and quality.
• Amneal's Brookhaven, New York site was selected for the FDA's Pre-Check Pilot Program, an acknowledgement of its strong U.S. manufacturing capabilities as the company expands domestic sterile injectable production.
• Severe flooding impacted one of Amneal's India manufacturing facilities one week prior to the call; all employees are safe, operations are expected to resume within a few weeks, with limited impact on a small number of products.

Pipeline and Product Momentum

• Affordable Medicines: The company is in a wave of high-value complex generic launches, with recent approvals for romidepsin, additional iohexol strengths, and ready-to-use sodium bicarbonate; lanreotide is expected to be approved in Q3 2026, with 12-15 additional high-value complex ANDA filings planned for 2026.
• Specialty: Traxxon (for Parkinson's disease) has strong Phase 4 data showing improved symptom control, with a new Phase 4 study planned for Q4 2026 in treatment-naive patients; Brachia (for migraine/cluster headache) continues to see strong uptake after launch; Amneal plans to expand its specialty pipeline via internal R&D and targeted acquisitions.
• Women's health transdermal patch demand increased following 2025 revised FDA guidance, and Amneal is expanding capacity to meet higher demand.

Amneal recorded total Q2 2026 net revenue of $796 million, a 10% year-over-year increase. The three business segments performed as follows:

1. Affordable Medicines: Q2 2026 revenue of $490 million, up 13% year-over-year, representing 61.6% of total company revenue. Growth was driven by a strong broad-based complex portfolio (including women's health products and injectables), higher naloxone sales, and $45 million in incremental revenue from recent new product launches (one ophthalmology, one urology).
2. Specialty: Q2 2026 revenue of $149 million, up 17% year-over-year, representing 18.7% of total company revenue. Growth outperformed expectations, driven by strong momentum for Traxxon (Kraxon), Unithroid, and Brachia.
3. Avcare: Q2 2026 revenue of $157 million, down 4% year-over-year, representing 19.7% of total company revenue. The decline was in line with expectations, as government channel growth was offset by planned pullback in low-margin distribution business.

Amneal raised its full year 2026 financial guidance for the second consecutive quarter, reflecting stronger-than-expected performance and accounting for the anticipated India facility flood impact:

• Revenue guidance increased by $50 million to a range of $3.1 billion to $3.2 billion, with high single-digit growth expected for both the Affordable Medicines and Specialty segments.
• Adjusted EBITDA guidance increased by $10 million to a range of $750 million to $780 million; the guidance includes a $20 million estimated negative impact from the India facility flooding.
• Adjusted EPS guidance increased by $0.01 to a range of $0.96 to $1.06, driven by higher profitability and $12 million in annual interest savings from a successful recent debt repricing.
• Capital expenditure guidance increased from ~$110 million to ~$150 million to fund expansion to meet higher demand for women's health products and U.S. injectable capacity.
• Operating cash flow guidance was maintained.
• The Kashiv acquisition is expected to close within the next few weeks, pending shareholder approval and closing conditions; Amneal expects net leverage to fall below 3x by 2028.

• Severe flooding at one of Amneal's manufacturing facilities in Gujarat, India is expected to create a $20 million negative impact to full year 2026 results, with temporary disruption to a limited set of products while operations resume over the next few weeks.
• Uncertainty around new U.S. administration tariff policies, with Amneal still waiting for additional details on the proposed changes.
• Potential launch delays for pipeline products (including lanreotide and the Xolair biosimilar) due to unforeseen FDA review timelines.
• Competition for new complex generic and biosimilar opportunities, though Amneal notes high barriers to entry for its prioritized complex products limit near-term competitive entry.

Q: Glenn Santangelo (Barclays) asked for confirmation of lanreotide and Xolair biosimilar launch timing, how much of these launches is included in 2026 guidance, and an update on the target of six commercial biosimilars by 2027. / A: Management confirmed lanreotide remains on track for Q3 2026 approval and launch, with conservative minimal revenue included in 2026 guidance. The Xolair biosimilar is expected to launch very late in 2026 or early January 2027, with no revenue included in 2026 guidance. The six commercial biosimilar target remains on track for 2027: the company already markets three, will launch two more this year, and the sixth (Xolair) will launch in early 2027, with more launches to follow in subsequent years.

Q: Katerina (JP Morgan) asked about potential impacts of new administration tariff proposals, and recent uptake trends for Traxxon. / A: Management noted Amneal has a large and expanding U.S. manufacturing network, and is waiting for additional details on the tariff policy, but will collaborate with the administration moving forward. For Traxxon, uptake is very strong: 80% of new scripts come from general neurologists (a shift from competing product Rytary), script growth continues week-over-week, and the Phase 4 data has been well received, with the goal to establish Traxxon as a first-line Parkinson's therapy.

Q: David Amsalim (Piper Sandler) asked about the market opportunity and competitive dynamics for newly approved iohexol SKUs and upcoming lanreotide, and Amneal's appetite for specialty M&A, particularly in neurology. / A: Management noted iohexol is a complex product with high entry barriers; it is a greater than $50 million opportunity that will contribute meaningful revenue starting in 2027. Lanreotide is also a complex drug-device combination with high barriers to entry, and Amneal expects to maintain a strong market position after Q3 launch. Amneal will prioritize specialty growth starting in 2026, leveraging its existing commercial infrastructure, and will actively pursue acquisitions of additional branded assets, particularly in CNS and oncology, alongside ongoing internal R&D investment.

Q: Matt Della Torre (Goldman Sachs) asked about key priorities for biosimilar and GLP-1 partnership programs over the next 6-12 months, and the market size for women's health transdermal patches post-FDA guidance. / A: For biosimilars, the top near-term priorities are integrating Kashiv, advancing the existing pipeline, and building capabilities to file 3-4 new biosimilars per year, including development of complex biosimilar drug-device combinations. The GLP-1 partnership with Pfizer is progressing well, and the manufacturing infrastructure Amneal is building for this program opens opportunities for additional peptide manufacturing for third parties or future generics. Management added that affordable medicines could add $1-2 billion in new revenue between 2026 and 2030 driven by existing product demand growth and new launches.